168 related articles for article (PubMed ID: 34295662)
1. Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis.
Zhou Z; Ren S; Chen L; Zhou C; Jiang T
Transl Lung Cancer Res; 2021 Jun; 10(6):2562-2572. PubMed ID: 34295662
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
4. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
6. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
7. Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
Tan A; Porcher R; Crequit P; Ravaud P; Dechartres A
J Clin Oncol; 2017 May; 35(15):1686-1694. PubMed ID: 28375786
[TBL] [Abstract][Full Text] [Related]
8. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
10. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K; Takeda T; Kataoka N; Yoshimura A; Nakanishi K; Yamanaka Y; Yoshioka H; Honda R; Uryu K; Fukui M; Chihara Y; Takei S; Kawachi H; Yamada T; Tamiya N; Okura N; Yamada T; Murai J; Shiotsu S; Kurata T; Takayama K
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894357
[TBL] [Abstract][Full Text] [Related]
11. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
Nie RC; Yuan SQ; Wang Y; Zou XB; Chen S; Li SM; Duan JL; Zhou J; Chen GM; Luo TQ; Zhou ZW; Li YF
Ther Adv Med Oncol; 2020; 12():1758835920929583. PubMed ID: 32595775
[TBL] [Abstract][Full Text] [Related]
12. The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.
Li S; Zhang S; Liu J; Yang C; Zhang L; Cheng Y
J Thorac Dis; 2019 Nov; 11(11):4453-4463. PubMed ID: 31903233
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.
Shukuya T; Mori K; Amann JM; Bertino EM; Otterson GA; Shields PG; Morita S; Carbone DP
J Thorac Oncol; 2016 Nov; 11(11):1927-1939. PubMed ID: 27496650
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
18. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
Front Oncol; 2022; 12():968517. PubMed ID: 36439448
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
Duan X; Du H; Qi R; Yuan M; Shi J
Exp Ther Med; 2023 May; 25(5):216. PubMed ID: 37123204
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
